Inhibition of PD-L1 by intratumoral injection of this engineered OV promoted their infiltrations and activations of neoantigen-specific T cells and immune cells, and presented neoantigens on tumor cells to effector T cells. This evidence concerns the gene CD274 and neoplasm.